Hikal

Price chart

Previous close

₹220.60

Open

₹221.50

Day high

₹230.98

Day low

₹219.60

Listed on NSE since 14 February 2001.

Market value

₹2,720.01 Cr

EPS (trailing)

₹-2.74

Price to book

2.32

Dividend yield

0.27%

Return on equity

-0.4%

Debt to equity

0.54

Profit margin

-0.3%

Beta

0.53

Volume today

4.01 L

Average volume

15.20 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Hikal’s results filed with NSE, consolidated (the whole group). Net profit is the share of Hikal’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Hikal’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals industries. The company operates in two segments, Pharmaceuticals and Crop Protection. It provides anti-convulsant, anti-inflammatory, analgesic, anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, anti-viral, and haemorheologic products; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also manufactures pesticides and herbicides, including diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it engages in contract research, custom synthesis, and custom manufacturing of intermediates and active pharmaceutical ingredients. The company operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is based in Navi Mumbai, India.

Industry

Drug Manufacturers - Specialty & Generic

Based in

Navi Mumbai

Employees

2,152

Company website · Profile: Yahoo Finance

No headlines name Hikal in the last day or two.

• Dividend - Re 0.40 Per Share

  Dividend · ex-date 4 September 2026

• Interim Dividend - Re 0.20 Per Share

  Dividend · ex-date 17 February 2026

• Dividend - Rs 0.80 Per Share

  Dividend · ex-date 2 September 2025

• Interim Dividend - Re 0.60 Per Share

  Dividend · ex-date 7 February 2025 · record date 8 February 2025

• Annual General Meeting

  Action · ex-date 10 September 2024

• Dividend - Re 0.60 Per Share

  Dividend · ex-date 4 September 2024

• Interim Dividend - Rs 0.60 Per Sh

  Dividend · ex-date 20 February 2024

• Annual General Meeting/Dividend - Rs 0.60 Per Share

  Dividend · ex-date 18 September 2023

Source: NSE. Latest first, 8 of 20.